Journal
JOURNAL OF IMMUNOLOGY
Volume 182, Issue 11, Pages 7287-7296Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0804288
Keywords
-
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro [2006068412-002]
- Istituto Superiore di Sanita Oncoproteomic [2007-527/B/3A/3]
Ask authors/readers for more resources
Colon cancer comprises a small population of cancer stem cells (CSC) that is responsible for tumor maintenance and resistant to cancer therapies, possibly allowing for tumor recapitulation once treatment stops. We previously demonstrated that such chemoresistance is mediated by autocrine production of IL-4 through the up-regulation of antiapoptotic proteins. Several innate and adaptive immune effector cells allow for the recognition and destruction of cancer precursors before they constitute the tumor mass. However, cellular immune-based therapies have not been experimented yet in the population of CSCs. Here, we show that the bisphosphonate zoledronate sensitizes colon CSCs to V gamma 9V delta 2 T cell cytotoxicity. Proliferation and production of cytokines (TNF-alpha and IFN-gamma) and cytotoxic and apoptotic molecules (TRAIL and granzymes) were also induced after exposure of V gamma 9V delta 2 T cells to sensitized targets. V gamma 9V delta 2 T cell cytotoxicity was mediated by the granule exocytosis pathway and was highly dependent on isoprenoid production by of tumor cells. Moreover, CSCs recognition and killing was mainly TCR mediated, whereas NKG2D played a role only when tumor targets expressed several NKG2D ligands. We conclude that intentional activation of V gamma 9V delta 2 T cells by zoledronate may substantially increase antitumor activities and represent a novel strategy for colon cancer immunotherapy. The Journal of Immunology, 2009, 182: 7287-7296.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available